HSL MedOnc Fellows

Official Twitter of the Medical Oncology Fellows at Hospital Sírio-Libanês. Tweets are our own.

[Thais Megid @MegidThais]

💊 Can DFS be used as a surrogate for OS in early-stage pancreatic cancer trials?
📈 In a meta-analysis of 29 RCTs (n=6777), DFS strongly correlated with OS (R=0.70 adjuvant | R=0.90 neoadjuvant).
📍 DFS may be a reliable surrogate endpoint for OS.
https://t.co/X6NagVudhU

[Camila Braganca Xavier @CamilaBragancaX]

After many years participating on both sides —as mentor and mentee— I can say that this is one of the most exciting moments of the meeting! Sign up for #ASCO25 encounters if you have the chance! ⁦@ASCOTECAG⁩ ➡️ Topical Mentoring Opportunities - ASCO https://t.co/NP9ficApmg

[David S. Hong MD @DavidHongMD]

One of our star Phase 1 fellows! @CamilaBragancaX Who will become a MDACC GI Onc doc! @MDAndersonNews

[Camila Braganca Xavier @CamilaBragancaX]

R0 resection is associated w/ OS outcomes for #PDAC. However, rare complications associated w/ mesopancreas excision as recurrent neurogenic shock can preclude patients from receiving proper adjuvant Tx. Check out our multidisciplinary report https://t.co/mkbC9ClnSG @FellowsHsl

[Camila Braganca Xavier @CamilaBragancaX]

Amazing work! This platform will help oncologists and patients across the country as it changes the landscape of clinical trial information and access in Brazil. This needs to be highlighted! @SBOC_Oncologia @ASCO @JCOGO_ASCO @jillfeldman4 @itsnot_pink

[Camila Braganca Xavier @CamilaBragancaX]

Amazing time w/ the @MDAndersonNews GI team! CCA pts may present to clinic with multiple co-occurrent genomic alterations 🎯🎯🎯 and target Tx sequencing strategies can improve survival outcomes compared with sequencing non-matched therapies. Happy to collaborate!

[Daniel Moore Palhares @DMoorePalhares]

Thrilled to receive @UofTDRO’s academic excellence in research award for 2nd consecutive yr! Grateful to my @sunnybrook mentors & coauthors @SahgalArjun Dr Soliman, Liam Lawrance, Angus Lau @jaydetsky. Tremendous & innovative research on ADC changes for recurrence prediction #GBM

[Camila Braganca Xavier @CamilaBragancaX]

Our ability to enhance #immunotherapy efficacy can be closely related to our capacity to overcome TME immunosuppression. Metabolism-directed targeted 🎯 therapies are (among others) great examples of #investigational #phaseI strategies to revert cold TME @ANaingMD @MDAndersonNews

[Duilio Rocha @duiliorocha_onc]

Comments on my personal top 4 #GI24 abstracts (1/4):

1. NETTER-2

177Lu-DOTATATE vs high dose octreotide as 1L treatment of G2 or G3 GEP-NET (Ki67 between 10% and 55%):

⬆️ PFS (22.5 vs 8.5 mo, HR 0.27)
⬆️ ORR (43% vs 9%)

I did not expect such good numbers.

@OncoAlert

1/

[Maria Isabel Achatz MD PhD @AchatzIsabel]

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline https://t.co/saqUP3ctOf

All women with breast cancer < 65 should get genetic testing. devem fazer o teste genético! Hospital Sírio-Libanês: única instituição da América Latina convidada.

[Camila Braganca Xavier @CamilaBragancaX]

Germline testing🧬 should be revisited for many cancer types to improve #cancercare. This ⁦⁦@ASCO⁩ update frames a beautiful work on the recommendations for #BreastCancer patients w/ the contribution of the 🇧🇷oncogenetic leader Maria Isabel Achatz https://t.co/aPNgR9qvzt

[Camila Braganca Xavier @CamilaBragancaX]

A rare case of primary carcinosarcoma of the peritoneum after risk-reducing BSO in a BRCA2 pathogenic variant carrier & BC survivor. 🧬 Thank you ⁦⁦@assad_daniele⁩ & team ⁦@hsiriolibanes⁩ #casereport #oncology #breastcancer #BRCA https://t.co/MHqSsz54Hv

[Camila Braganca Xavier @CamilaBragancaX]

Just had a great time presenting my work on OS predictors among TMB-low #cancer patients treated with #Immunotherapy at #ESMO23 & with the plus of receiving the visit from the IO master and @JIPOEditors mentor @ANaingMD ! Thank you for the support 🇧🇷 @jardim_denis @GalanteLab

[Camila Braganca Xavier @CamilaBragancaX]

⏰ Countdown to #ESMO23 @myESMO! Meet us on Saturday and check out our work on survival predictors among TMB-low #cancer patients treated with #immunotherapy @GalanteLab @pafgalante @cdiegoholanda @AwniBeatriz @jardim_denis

[Camila Braganca Xavier @CamilaBragancaX]

📢 Great retrospective from @MayoClinic !
📍dMMR/MSI PDAC are rare (1-2% of PDAC)
♦️KN158 outcomes for M+ are poorer than RWD but grant ICI agnostic approval
🆚 could we de-escalate bi/tri modality treatment?
❇️ Guidelines should be revised!
#immunotherapy #PancreaticCancer

[Camila Braganca Xavier @CamilaBragancaX]

🌎🖥️ always connected @hsiriolibanes @FellowsHsl

[Ghassan Abou-Alfa @GABOUALFA]

Thank you @h_sirio_libanes Brenda Gumz on a superb @MSKCancerCenter @MSK_DeptOfMed #GIFellows Monthly Conference. Great learning and engagement on #insulinoma.

[Camila Braganca Xavier @CamilaBragancaX]

Happy to share that I’m starting a new position as an Editorial Fellow at @JIPOEditors! Grateful for the opportunity to work w/ the terrific editorial board while peer reviewing, proofreading, and disseminating content on #immunotherapy and #precisiononcology via social media!

[Camila Braganca Xavier @CamilaBragancaX]

Countdown to #ASCO23 ‼️

[Denis Jardim @jardim_denis]

Check our poster at #GU23. Adverse cardiovascular and thromboembolic events during intense NeoAdj Androgen Blockade before Prostatectomy. Raise concerns for this future strategy. ⁦@FellowsHsl⁩ ⁦@DiogoAssed⁩